BIOLINERX
Careers | Contact Us
search

Press Releases
December 23, 2014
Omega Pharma to develop and commercialize novel skin treatment for OTC use in Europe and additional selected countries
First product expected to reach the market in 2016
December 16, 2014
Global pharmaceutical company makes initial $10 million equity investment in BioLineRx
BioLineRx to host conference call today, December, 16 at 10:00 a.m. EST 

December 12, 2014
Clinical trials in three additional indications for BL-8040 to be initiated in 2015
Development strategy presented today at BioLineRx investor meeting in New York 

December 8, 2014
Data show six-fold increase in mobilization of AML cells from bone marrow; Treatment with BL-8040 as single agent led to 70% decrease in AML cells in bone marrow and 3.5-fold increase in AML cell apoptosis 
November 5, 2014
Optimal safe dose of BL-7010 determined for upcoming randomized efficacy study
Lack of systemic exposure of BL-7010 likely supports medical-device classification in Europe

November 3, 2014
Amendment will include testing of higher doses, resulting in increase of total study population to up to 70 patients
Changes unanimously recommended by Clinical Advisory Board


November 3, 2014
Management to hold conference call at 10:00 a.m. EST
October 31, 2014
Results of first-in-man study published in Circulation: Cardiovascular Interventions
BCM (BL-1040) is currently undergoing PRESERVATION I, a CE Mark registration trial conducted by Bellerophon, with study completion anticipated in mid-2015

141-150  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next